Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis
1 finding from 1 review
Good or better behaviour · Children and adolescents (0 to 16 years) needing dental treatment
It is very uncertain whether chloral hydrate changes good or better behaviour compared with placebo (including no intervention) (very low certainty).
1 finding from 1 review
Diarrhoea · patients with Shigella dysentery
It is very uncertain whether oral gentamicin changes diarrhoea at compared with nalidixic acid (very low certainty).
1 finding from 1 review
Relapse ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Interruptions to cancer treatment (radiotherapy breaks longer than two days) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in interruptions to cancer treatment (radiotherapy breaks longer than… compared with placebo; GRADE not reported.
1 finding from 1 review
Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse events · Adults receiving chemotherapy alone for colorectal cancer
1 finding from 1 review
Apixaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8544 participants
High
Rivaroxaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
3 studies · 21870 participants
High
no estimate extracted
3 studies · 21870 participants
Moderate
no estimate extracted
3 studies · 21870 participants
High
Dabigatran (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
Caries (DMFT) and enamel defects · Preterm children (about 8 years old) in the United Arab Emirates (Dubai)
One study found preterm children had higher DMFT and a fourfold higher prevalence of enamel defects than full-term children (narrative synthesis; not GRADE-rated).
1 finding from 1 review
Alshehhi et al. (Dubai) reported a significantly higher mean DMFT (1.00 vs 0.38) and a 4-times higher prevalence of enamel defects (58.15% vs 24.2%; OR 4.33, 95% CI 2.01-9.36) in preterm vs full-term children, highest…
1 study
GRADE not reported
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in symptomatic deep vein thrombosis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).
1 finding from 1 review
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found